Cancer-Associated Fibroblasts and Prostaglandin E2 Signaling in Gastric Cancer: Immunometabolic Mechanisms and Implications for Immunotherapy Resistance
International Journal of Molecular Sciences · 25.10.2026 · 27 (21) · 9544
DOI: 10.3390/ijms27219544 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.10.2026. Verfasst von Chongxuan Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Dinoprostone, Cancer-Associated Fibroblasts, Signal Transduction. Die Arbeit nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Liaoning Provincial Science and Technology.
Abstract (Originalsprache)
Cancer-associated fibroblasts (CAFs) and prostaglandin E2 (PGE2) signaling have each been implicated in resistance to immune checkpoint inhibitors (ICIs) in gastric cancer. CAFs are associated with immune exclusion, whereas PGE2 can suppress CD8+ T-cell responses through prostaglandin E receptors 2 and 4 (EP2 and EP4) and alter dendritic-cell and myeloid-cell function. Whether PGE2 produced by CAFs directly contributes to ICI resistance in gastric cancer, however, remains unclear. To distinguish association from functional involvement, we synthesize the available literature into a conceptual continuum describing the possible contribution of PGE2 to CAF-associated immunotherapy resistance. At the Model A end, PGE2 may accompany CAF activation or local inflammation, whereas other CAF-associated mechanisms, including extracellular matrix remodeling, lactate, and CXCL12 signaling, may account for much of the resistance phenotype. At the Model B end, PGE2 may make an identifiable functional contribution to resistance beyond these alternative mechanisms, although the cellular source of the relevant PGE2 remains unresolved. These models represent interpretive endpoints derived from the available evidence rather than experimentally validated resistance subtypes or an established CAF-derived PGE2 pathway. Clinical findings with the EP4 antagonist ONO-4578 support the therapeutic potential of receptor blockade but do not identify the cellular source of PGE2 involved. Key unresolved questions concern the cellular sources of PGE2, its relationship with immune exclusion, and whether PGE2-related markers improve the prediction of ICI response beyond established indicators.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
- The Fourth Clinical College, China Medical University, Shenyang 110122, China.
- School of Stomatology, China Medical University, Shenyang 110002, China.
ORCID-Profile: Chongxuan Xu
Förderung
- Liaoning Provincial Science and Technology
Zitieren
APA
Xu, C., Wang, Y., Zhang, Q., Dong, Y., Yuan, M., Li, D., Deng, S., & Du, J. (2026). Cancer-Associated Fibroblasts and Prostaglandin E2 Signaling in Gastric Cancer: Immunometabolic Mechanisms and Implications for Immunotherapy Resistance. International Journal of Molecular Sciences, 27(21), 9544. https://doi.org/10.3390/ijms27219544
Vancouver
Xu C, Wang Y, Zhang Q, Dong Y, Yuan M, Li D, et al. Cancer-Associated Fibroblasts and Prostaglandin E2 Signaling in Gastric Cancer: Immunometabolic Mechanisms and Implications for Immunotherapy Resistance. International Journal of Molecular Sciences. 2026;27(21):9544. doi:10.3390/ijms27219544
BibTeX
@article{Xu2026,
author = {Xu, Chongxuan and Wang, Yihan and Zhang, Qiaoqiao and Dong, Yihe and Yuan, Mengjing and Li, Dongxuan and Deng, Shiyang and Du, Jiang},
title = {Cancer-Associated Fibroblasts and Prostaglandin E2 Signaling in Gastric Cancer: Immunometabolic Mechanisms and Implications for Immunotherapy Resistance},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {21},
pages = {9544},
doi = {10.3390/ijms27219544}
}
EUVIMED